Status:

WITHDRAWN

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

Lead Sponsor:

Negovsky Reanimatology Research Institute

Collaborating Sponsors:

Demikhov Municipal Clinical Hospital 68

Conditions:

Acute Respiratory Distress Syndrome

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

At the beginning COVID-associated lung injury was considered as typical ARDS, hence respiratory and nonrespiratory treatments were delivered according to general principles for this kind of illness. T...

Detailed Description

COVID 19 pandemic is a serious challenge for International medical community. There is lack of knowledge about the nature and character of the lung injury caused by this kind of infection. At the begi...

Eligibility Criteria

Inclusion

  • Severe pulmonary coronavirus disease 19 (COVID 19) with suspect for MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome)
  • P/F ratio \<200 mmHg\> 70 mmHg
  • a.) Contrast CT scan positive for pulmonary thrombosis, OR b.) Contrast CT scan negative for pulmonary thrombosis:
  • D-Dimer \> 10 mcg/mL, OR
  • 5 \< D-dimer \< 10 mcg/mL and C Reactive Protein (CRP) \> 100 mg/dL

Exclusion

  • Age \< 18
  • Pregnancy or breastfeeding
  • Known allergy to iodinated contrast dye
  • Severe vasoplegic shock: norepinephrine \> 300 ng/kg\*min
  • Glomerular Filtration rate \< 30 ml/min
  • Active bleeding or absolute contraindication to anticoagulant therapy (Stroke (intracranial hemorrhage, hemorrhagic stroke), including a history of the last 6 months.; cancer of the Central nervous system and other localities with an increased risk of bleeding, vascular aneurysm, traumatic open heart massage, obstetric delivery, General operations, severe uncontrolled hypertension, gastric ulcer and 12-duodenal ulcer (for 3 months. from the moment of exacerbation), arterial or venous malformations, liver failure, liver cirrhosis, portal hypertension, esophageal varicose veins, active hepatitis).

Key Trial Info

Start Date :

October 15 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 15 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04453371

Start Date

October 15 2020

End Date

February 15 2021

Last Update

March 12 2021

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.